News Channels

26 Jul 2017 First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer
26 Jul 2017 Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1
26 Jul 2017 Faslodex receives eu approval as first-line therapy for advanced breast cancer
26 Jul 2017 Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
26 Jul 2017 Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration
26 Jul 2017 Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
25 Jul 2017 Trovagene Announces Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075, its Polo-like Kinase 1 (PLK1) Inhibitor
25 Jul 2017 Frontier Biotech licenses 3BNC117, a novel broad-spectrum HIV neutralizing antibody
25 Jul 2017 Kezar Life Sciences Announces Successful Completion of Phase 1a Study and Secures $50 Million in Series B Financing
25 Jul 2017 Viriom Obtains First Market Approval of Elsulfavirine (Elpida®) for Treatment of HIV-1 Infection in Russia
25 Jul 2017 Axsome Therapeutics Announces AXS-06 (MoSEIC™ Meloxicam and Esomeprazole) Meets Primary Endpoint in Phase 1 Clinical Trial
25 Jul 2017 Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN
25 Jul 2017 The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE
25 Jul 2017 Neon Therapeutics and Apexigen Announce Immuno-Oncology Clinical Trial Collaboration
25 Jul 2017 NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials
25 Jul 2017 Janssen Announces Phase 3 Pivotal Study Results for Darunavir-Based Complete Treatment Regimen
25 Jul 2017 Takeda and BioSurfaces Announce Joint Research Program to Explore Promising Devices to Treat Gastrointestinal Diseases
25 Jul 2017 ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings
25 Jul 2017 Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection
25 Jul 2017 Lilly and Incyte Provide Update on Baricitinib

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top